Keep up to date with the latest news and opinions in the biotechnology investment community.
In recent years, oncologists have gained a vital new weapon in the ongoing fight against cancer through the rise of DNA damage response (DDR) inhibitors, a form of precision medicine which kills cancer cells by preventing them from repairing damage to their DNA.
In the last two decades more than one hundred candidate medicines for Alzheimer’s have failed in clinical trials. Billions of dollars have been lost. So why should investors have a look again at Alzheimer’s?
Around the globe, different research institutions and companies are racing to try and develop an Alzheimer’s vaccine, an immunisation which can be administered to those thought to be at risk. If they succeed, it would be a game changing moment in the fight against the disease.
Subscribe to our newsletter.
Keep up to date with the latest news in the biotech investment community.